Pfizer Secures Exclusive Rights to Starna Therapeutics' In Vivo CAR-T Programs for Autoimmune Diseases
Trendline

Pfizer Secures Exclusive Rights to Starna Therapeutics' In Vivo CAR-T Programs for Autoimmune Diseases

What's Happening? Pfizer (NYSE:PFE) has entered into an agreement to secure exclusive rights to Starna Therapeutics' in vivo CAR-T programs for autoimmune diseases, specifically for regions outside Greater China. This strategic move centers on Starna's proprietary in vivo CAR-T platform, which aims
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.